Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 3, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF REVACCINATION WITH RESPIRATORY SYNCYTIAL VIRUS STABILIZED PREFUSION F SUBUNIT VACCINE (RSVPREF) IN IMMUNOCOMPROMISED ADULTS

NCT07768345 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07768345
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07768345 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 3, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF REVACCINATION WITH RESPIRATORY SYNCYTIAL VIRUS STABILIZED PREFUSION F SUBUNIT VACCINE (RSVPREF) IN IMMUNOCOMPROMISED ADULTS
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Recruiting
Start date
August 31, 2026
Completion date
February 2, 2028
Enrollment
440 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory syncytial virus (rsv)